1. Scrip
  2. >>Business

Sanofi Takes €80M BioNTech Stake & Extends 2015 Deal

 
• By Mike Ward

BioNTech gets an €80m boost to its reserves as Sanofi takes equity stake as partners extend 2015 deal and advance an mRNA-based cancer immunotherapy into clinic against multiple solid tumors

Sean Marett
BioNTech's Marett says Sanofi Equity Stake Solidifies Partnership • Source: BioNTech

German biotech BioNTech AG has added Sanofi as a strategic investor as the French pharma giant takes an €80m equity stake and agrees to extend a 2015 research collaboration between the two companies. Concomitantly, the partners have agreed to co-develop the first cancer immunotherapy candidate from the collaboration that is entering clinical testing in multiple solid tumors.

In the original deal (Also see "Sanofi Hopes BioNTech Pact Can Help Reboot Cancer Prospects" - Scrip, 3 November, 2015.), the partners agreed to discover and develop up to five mRNA-based cancer immunotherapies against undisclosed targets. Sanofi paid $60m in an upfront payment and near-term milestones for exclusive, worldwide rights to candidates that emerge from the deal, while BioNTech had an option to co-develop and co-commercialize two candidates in the EU and U

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No Supply Disruption In US

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.